Latest news and press releases about Iovance Biotherapeutics, Inc. (IOVA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials.
Price
| Price | $9.87 |
| Market Cap | $4.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.04 |
| EV / EBITDA | -15.66 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -40.51% |
| Return on Invested Capital | -36.60% |
| Return on Assets | -31.62% |
| Gross Margin | 116.30% |
| Operating Margin | -92.72% |
| Net Margin | -89.09% |
Related companies: ATXS · AVBP · CTMX · DNA · ERAS · MBX · MGTX
Explore sector: Healthcare · Biotechnology
More sections of IOVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks